LABT is Lakewood-Amedex Biotherapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $1.94. Market cap: $5M.
Stock snapshot
| Price | $1.94 |
| Market cap | $5M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About LABT
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Related non-dividend companies
Other non-dividend stocks investors research alongside LABT. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is LABT's current stock price?
LABT (Lakewood-Amedex Biotherapeutics, Inc.) is currently trading at $1.94.
Does LABT pay a dividend?
LABT (Lakewood-Amedex Biotherapeutics, Inc.) does not currently pay a regular dividend.
Track LABT in DiviDrip
Add LABT to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search LABT and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.